U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06987695) titled 'Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease' on May 02.
Brief Summary: The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with >= 5% reduction in body weight.
Study Start Date: June 02
Study Type: INTERVENTIONAL
Condition:
Obesity Disease
Intervention:
DRUG: Maridebart cafraglutide
Maridebart cafraglutide will be administered SC.
DRUG: Placebo
Placebo will be administered SC.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Amgen
Disclaimer: Curat...